VA-FLUENCE
Fluence , a Siemens and AES company, today unveiled its sixth-generation energy storage technology stack combining factory-built hardware, advanced software and data-driven intelligence. Drawing on more than 12 years of industry leadership and innovation, the new technology is changing the way energy storage systems are built and operated — making them simpler, safer, faster and more cost-effective to deploy at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005326/en/
The technology stack creates the foundation for three purpose-built systems, GridstackTM , SunstackTM and EdgestackTM , that are configured for grid, renewable and commercial & industrial (C&I) applications, respectively, while easily addressing the need for larger systems and larger fleets of systems. Fluence has already been selected by leading customers such as Enel, LS Power, sPower and Siemens for 800 megawatts, 2300 megawatt-hours, of projects using the new technology.
“Energy storage applications require highly flexible systems that can be tailored to specific markets and customer needs,” said Fluence CTO Brett Galura. “Until now, customers were forced to choose between custom-built solutions or inflexible, vertically integrated products. This sixth-generation technology combines our proprietary dataset – among the industry’s largest – and our deep industry experience to deliver unparalleled intelligence and flexibility, while adding the benefits of mass production to standardize safety features and significantly reduce the time and cost needed to deploy energy storage. Over the past decade, Fluence has reduced the total cost of energy storage systems by 90 percent; our new technology stack focuses on driving down the non-battery costs of energy storage systems by up to 25 percent, while empowering gigawatt-sized deployments.”
Fluence’s new technology stack includes three components:
- Fluence IQ : Digital intelligence engines use data and machine learning to improve system decision-making, manage battery degradation, reduce operating costs and optimize energy market dispatch.
- Fluence Operating System (OS) : Built on a decade of digital control system development, the fully integrated operating platform combines comprehensive controls, system visibility and asset management to improve asset performance at a single site or across entire fleets.
- Fluence Cube : The factory-assembled building block is 4-5x more modular than traditional systems and incorporates the latest technologies for rapid installation and scale, consistent operations & maintenance and improved quality control.
Fluence Cube, OS and IQ incorporate enhanced safety features to meet the most stringent safety standards, such as NFPA 855 and UL 9540A. Together, they provide the foundation for three pre-configured energy storage systems optimized for specific market segments and project needs:
- Gridstack : A utility-scale system designed for the most demanding grid applications (such as T&D enhancement, frequency regulation and capacity peak power), with industry-leading reliability and safety.
- Sunstack: A PV-optimized, co-located system designed to improve and expand the capabilities of solar generation with firm renewable energy delivery and additional grid services.
- Edgestack : A commercial & industrial system designed to support 500+ kW applications with rapid deployment and minimum footprint to reduce demand charges and provide critical power.
Major global power suppliers and industrial customers have already committed to deploy Fluence’s sixth-generation technology in Asia Pacific, North America and Europe. Siemens is delivering Gridstack and Edgestack for customers in Germany, Portugal and Finland.
“Battery storage is a rapidly growing segment and crucial for the energy transition. For the cost-efficient and fast execution of projects in the area of distributed energy, microgrids and eMobility infrastructure, the productization and modularization of storage technologies are decisive. With the new stack & OS approach, Fluence has a unique system providing cutting-edge safety,” said Jean-Christoph Heyne, Global Head of Future Grids, Siemens AG.
“Cost-competitive technologies, aggressive emissions targets and increased need for grid reliability and resilience are driving global utility and C&I demand for energy storage, which BloombergNEF predicts will attract more than $560 billion in investment by 2040,” said Fluence CEO Manuel Perez Dubuc. “What separates our carbon-intensive past from a sustainable future is market inflection. With the introduction of our next-generation design, Fluence is helping drive that inflection, making it more cost-effective, faster and safer to replace smokestacks with tech stacks that provide communities around the world with cleaner, more resilient energy systems.”
About Fluence
Fluence, a Siemens and AES company, is the global market leader in energy storage technology solutions and services, combining the agility of a technology company with the expertise, vision and financial backing of two well-established and respected industry giants. Building on the pioneering work of AES Energy Storage and Siemens energy storage, the company’s goal is to create a more sustainable future by transforming the way we power our world. Providing design, delivery and integration, Fluence offers proven energy storage technology solutions that address the diverse needs and challenges of customers in a rapidly transforming energy landscape. The company currently has more than 2.1 gigawatts of projects in operation or awarded across 22 countries and territories worldwide. Fluence topped the Navigant Research utility-scale energy storage leaderboard in 2018 and was named one of Fast Company’s Most Innovative Companies in 2019.
To learn more about Fluence, please visit: fluenceenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005326/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom